Information Products on Pharmaceuticals - Renouf Publishing Co. Ltd.

oms-catalogue 15/07/03 11:32 Page 6
ECONOMICS AND FINANCING
Free of charge
For information on availability of these documents,
please refer to: www.who.int/medicines
6
Guide to Drug Financing
Mechanisms
A practical guide to the use
of economic criteria to analyse a
country’s pharmaceutical sector and
identify ways to improve the drug
supply. Addressed to decisionmakers
responsible for formulating
drug policies, the book aims to
facilitate the analysis of expenditure
on drugs within the context of
a government’s overall economic
policies and priorities. With this
goal in mind, the book explains the
many complex economic factors
that influence the drug supply and
identifies the corresponding policy
options available for introducing
changes in different situations.
by J. Dumoulin, M. Kaddar, and
G.Velásquez
1998, vii + 55 pages [E, F]
ISBN 92 9036 068 2
Swiss francs 19.–/US $17.10
In developing countries: Sw.fr. 13.30
Order no. 1150461
Cost-containment Mechanisms
for Essential Medicines,
including Antiretrovirals,
in China
Health Economics and Drugs EDM Series,
No. 13
2002,27 pages [E]
WHO/EDM/PAR/2003.6
Electronic access: http://www.who.int/
medicines/library/par/who-edm-par-2003-
6/CostContainmentEnglish.pdf
Implications of the DOHA
Declaration on the TRIPS
Agreement and Public Health
This document considers the
implications of the Doha Declaration,
and includes discussions on compulsory
licensing and transfer of technology
to countries with little or no manufacturing
capacity or insufficient market
demand.
Health Economics and Drugs Series, No. 12
2002, 68 pages [E, F, S*]
WHO/EDM/PAR/2002.3
Electronic access: http://www.who.int/
medicines/library/par/who-edm-par-2002-
3/doha-implications.doc
Network for Monitoring the
Impact of Globalization and
TRIPS on Access to Medicines
The last decade has witnessed a sharp
acceleration in the processes of
economic globalization and a major
increase in the number, and expansion
of the scope, of international trade
agreements. This is a report of a
meeting held in 2001 at which WHO
initiated a process to monitor and
analyze the impact of trade agreements
on access to drugs in partnership
with four WHO collaborating
centres in Brazil, Spain, Thailand
and the United Kingdom.
Health Economics and Drugs Series, No. 11
2002, 67 pages [E]
WHO/EDM/PAR/2002.1
Electronic access: http://www.who.int/
medicines/library/par/who-edm-par-2002
1/networktrips.pdf
Public-Private Roles
in the Pharmaceutical Sector
Implications for Equitable Access
and Rational Drug Use
Aimed at policy makers at country,
regional and international levels, this
document provides a practical guide
to how changing public-private roles in
the pharmaceutical sector may affect
drug accessibility and rational use.
Health Economics and Drugs Series, No. 5
1997, 102 pages [E, F, S]
WHO/DAP/97.12
Electronic access: http://www.who.int/me
icines/library/dap/who-dap-97-12/who-dap
97-12.htm
Globalization and Access
to Drugs
Perspectives on the WTO/TRIPS
Agreement.
The impact of globalization on access
to drugs is of increasing interest, and
this document informs people in the
health sector with no legal background
about this complex issue.
Health Economics and Drugs Series, No. 7
1998, 98 pages [E, F, S, C, Ar]
WHO/DAP/98.9 Revised
Electronic access: http://www.who.int/
medicines/library/dap/who-dap-98-9-
rev/who-dap-98-9.htm
Health Reform and Drug
Financing
Selected Topics
This document discusses reform primarily
from the perspective of certain
financial aspects of health-public
financing, health insurance, user
charges, donor financing and drug
donations, and development loans.
Health Economics and Drugs Series, No. 6
1998, 44 pages [E, F, S]
WHO/DAP/98.3
Electronic access: http://www.who.int/
medicines/library/dap/who-dap-98-3/
who-dap-98-3.htm